Dr. Gujrathi is the Co-Founder of Gossamer Bio. Prior to joining Gossamer Bio, Dr. Gujrathi served as Chief Medical Officer of Receptos, Inc. from June 2011 until the company’s acquisition by Celgene Corporation in August 2015. Prior to joining Receptos, she was Vice President of the Global Clinical Research Group in Immunology at Bristol Myers Squibb from 2008 to 2011. Dr. Gujrathi worked at Genentech from 2002 to 2008 where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group and served as the Avastin Franchise Team Leader. From 1999 to 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi received her B.S. with highest distinction in Biomedical Engineering and M.D. from Northwestern University in their accelerated Honors Program in Medical Education. She completed her Internal Medicine Internship and Residency at Brigham and Women’s Hospital, Harvard Medical School. She received additional training at University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.
Jesse J. Wu is a Senior Advisor focused on Asia buyout opportunities. Mr. Wu served as Chairman of China at Johnson & Johnson until May 2016. During his 26-year tenure at Johnson & Johnson, Mr. Wu served across multiple roles, including as Worldwide Chairman of the Johnson & Johnson Consumer Group and Company Group Chairman for Global Markets. He has 30 years of experience in the healthcare and related sectors. He serves as Member of Advisory Board at Duke Kunshan University. Mr. Wu earned his undergraduate degree in economics from National Chengchi University in Taiwan. He holds an M.B.A. degree from Duke University’s Fuqua School of Business.
Dr. Janda has been the Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute (TSRI) since 1996. Dr. Janda has been the Director of the Worm Institute of Research and Medicine (WIRM) at The Scripps Research Institute since 2005. He has served as an Associate Professor/Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at The Scripps Research Institute, since 1996. Over a career of almost 25 years, Dr. Janda has provided numerous seminal contributions and is considered one of the first scientists to merge chemical and biological approaches into a cohesive research program. He has been a
Director of Sorrento Therapeutics, Inc. since April 15, 2012. He serves as Member of Scientific Advisory Board of Medisyn Technologies, Inc. He serves on the Scientific Advisory Boards of Singapore Ministry of Education (“MOE”), EP1 Physical Sciences. He was a Scientific Advisor of Materia, Inc. He has published over 425 original publications in peer-reviewed journals and founded the biotechnological companies CombiChem, Drug Abuse Sciences, and AIPartia. Dr. Janda received B.S. degree in Clinical Chemistry from University of South Florida in 1980 and M.S. from University of Arizona in 1983. He holds Ph.D./doctoral degree from the University of Arizona with Robert B. Bates in natural product total synthesis in 1984.
Lawrence J. Cheskin, MD, FACP, FTOS directed the Johns Hopkins Weight Management Center, a multidisciplinary clinical research and treatment program that he founded in 1990. Dr. Cheskin is Professor and Chair of the Department of Nutrition and Food Studies, Interim Chair of the Department of Global and Community Health, Co-Principal Investigator of the Mason Cohort: Health Starts Here study, and Adjunct Professor at Johns Hopkins School of Medicine. He received his medical degree from Dartmouth, and postdoctoral training at Yale-New Haven Hospital. He has written over 200 peer-reviewed publications, 6 books, and is frequently cited in the media on issues related to obesity, nutrition, and dieting.
Dr. Chun is currently professor and the senior vice president of Neuroscience Drug Discovery at Sanford Burnham Prebys Medical Discovery Institute, with over 27 years of experience in academia and industry. He currently leads a team of 25 researchers in the study of genomic mosaicism (DNA sequence variation in brain cells) and lysophospholipid receptor signaling to understand and develop drug treatments for brain diseases such as Alzheimer’s disease, multiple sclerosis, and hydrocephalus. Dr. Chun previously held professorships at The Scripps Research Institute, the University Of California San Diego School Of Medicine, and also headed the Department of Molecular Neuroscience at Merck Research Laboratories. Dr. Chun has published ~300 scientific articles and three patents. He received M.D. and Ph.D. (Neuroscience) degrees through the Medical Scientist Training Program at Stanford University School of Medicine, and was a Helen Hay Whitney Fellow at the Whitehead Institute for Biomedical Research/MIT.
An orthopedic surgeon, inventor, and entrepreneur, Dr. Hank Wuh has led the development of over twenty biomedical and consumer healthcare products. Dr. Wuh is founder and CEO of SKAI Ventures, a hybrid of venture capital and technology accelerator focused on transforming novel, ingenious ideas into disruptive innovations and high growth companies. SKAI Venture’s motto is “Invent. Disrupt. Inspire,” and its mission is to invent the future, disrupt the status quo, and to inspire young entrepreneurs and innovators to follow their dreams. Some of SKAI Ventures’ portfolio companies include Cellular Bioengineering, Inc., developing the world’s most advanced, bioengineered cornea for transplantation to restore vision for blindness; TruTag Technologies, innovator of an edible security platform to address the trillion dollar global counterfeit problem and the issue of food and medicine safety; SKAI Vision Institute, a center of excellence restoring sight for visually impaired patients from throughout Asia and Pacific; and Endoscopy Institute of Hawaii, a center of excellence providing state of the art screening and early detection of gastro-esophageal and colon cancer. Dr. Wuh